Neupogen

Active ingredient
Darbepoitin alfa, Pegfilgrastim, Filgrastim
Medical indication
Epo-Präparat
Pharma Company
Amgen GmbH
Total Number of Doctors1
19 doctors
Total Number of Patients2
281 patients
Total minimum fees planned3
120,675.45 €

Observational Studies including Neupogen

Drug No. of doctors1 No. of patients2 Payment per patient3
Aranesp / Neulasta / Neupogen 19 281 429.45 €

Background

Independent journalism needs independent funding

Others can write stories. We want to reveal. We are the first investigative newsroom in Germany, which is independent, ad-free, and non-profit.

For us, the core of journalism means uncovering injustice and shortcomings in society. That’s why we investigate corruption in the health system, politicians abusing their power, and an elite that believes that rules are for the others.

To do our job, we need people, who support us. We ask you, too, to become a member and enable the work of 16 investigative journalists at CORRECTIV.

We are convinced that without independent and critical media, democracy fought for and won by our ancestors, cannot survive for long.